A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ellis, Peter
  • Chu, QS
  • Leighl, NB
  • Laurie, SA
  • Trommeshauser, D
  • Hanft, G
  • Munzert, G
  • Gyorffy, S

publication date

  • May 20, 2008